A Phase III Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia

Haisco Pharmaceutical Group

Status and phase

Completed

Phase 3

Conditions

Sedation or Anesthesia

Treatments

Drug: HSK3486

Drug: Propofol

Study type

Interventional

Funder types

Industry

Identifiers

NCT03674008

HSK3486-301

Details and patient eligibility

About

This is a Phase III, randomized, double-blind, propofol-controlled, parallel-design, multi-center study to evaluate the efficacy and safety of HSK3486 for sedation or anesthesia in patients undergoing colonoscopy and gastroscopy.

The study will enroll approximately 280 adults. The maximum study duration is anticipated to be up to nine months.

Enrollment

280 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Scheduled to undergo a diagnostic or therapeutic colonoscopy or gastroscopy;
Male or female patients, ASA grade I~II, aged ≥ 18 and < 65;
Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;
During screening and baseline, the respiratory rate ≥10 and ≤24, SpO2 when inhaling ≥95%, SBP≥90mmHg, DBP≥60mmHg, HR≥60 and ≤100;
Patient can understand the procedure of this study and is willing to comply with study requirements. The patient can sign the ICF voluntarily.

Exclusion criteria

Patients were contraindicated in general anesthesia.
Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products or a medical condition such that these agents were contraindicated.
The patient has some history or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period.
Patients with a history of drug or ethanol abuse with the past 3 months.
Patients with respiratory management difficulties (Modified Mallampati grade IV).
Patients in receipt of any investigational drug within 30 days before screening.
Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics within 72 hours prior to baseline.
Abnormal laboratory results consisting of any of the following:

neutrophil count≤ 1.5×109/L； 2）platelet≤ 80×109/L； 3）hemoglobin≤ 90 g/L; 4）aspartate aminotransferase≥ 1.5×ULN； 5）total bilirubin≥ 1.5×ULN； 6） serum creatinine≥ 1.2×ULN. 9. Pregnant women or female patients with a positive serum or urine human chorionic gonadotropin pregnancy test at screening or baseline or lactating female patients.

Patients with an inability to communicate well with the investigator, or deemed unsuitable according to the investigator (in each case providing a reason).